[
  {
    "trial_id": "NCT01922921",
    "mcode_mappings": [
      {
        "resourceType": "CancerCondition",
        "clinicalStatus": "active",
        "verificationStatus": "confirmed",
        "code": {
          "coding": [
            {"system": "http://snomed.info/sct", "code": "254837009", "display": "HER2/Neu Positive"},
            {"system": "http://snomed.info/sct", "code": "373439003", "display": "Recurrent Breast Carcinoma"},
            {"system": "http://snomed.info/sct", "code": "443883004", "display": "Stage IV Breast Cancer"}
          ]
        },
        "subject": {"reference": "Patient/1"},
        "onsetDateTime": "2014-02-05"
      },
      {
        "resourceType": "TumorMarkerTest",
        "marker": "HER2",
        "method": "IHC or FISH",
        "result": "Positive",
        "date": "2014-02-05"
      },
      {
        "resourceType": "Treatment",
        "treatmentType": "Immunotherapy",
        "agents": ["HER2 ICD peptide-based vaccine", "Trastuzumab", "Pertuzumab", "Polysaccharide-K"],
        "arm": "Arm I (placebo) / Arm II (polysaccharide-K)",
        "startDate": "2014-02-05",
        "endDate": "2021-09-01"
      },
      {
        "resourceType": "Outcome",
        "primaryOutcome": "Grade 3 or higher toxicity",
        "secondaryOutcomes": ["NK cell IFN-gamma production", "CD107a expression", "Epitope spreading", "Serum cytokine/chemokine changes", "Serum TGF-beta levels", "PFS", "OS"],
        "resultSummary": "No major toxicity, immune response observed, survival tracked."
      }
    ],
    "source_text_fragment": "Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy. Vaccines made from HER2 intracellular domain (ICD) peptide may help the body build an effective immune response to kill tumor cells that express HER2. Polysaccharide-K may stimulate the immune system in different ways and stop tumor cells from growing."
  }
]
